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Human immunodeficiency virus type 1 (HIV-1) fusion with its target cells is initiated by sequential interactions between its envelope
glycoprotein, CD4, and a co-receptor, usually CCR5 or CXCR4. Small molecules that bind to CCR5 and prevent its use by R5 HIV-1 strains
are now being developed clinically as antiviral drugs. To test whether a block to CCR5 promotes the replication of viruses that enter cells via
CXCR4 and are associated with accelerated disease progression, we administered a small molecule CCR5 inhibitor, CMPD 167, to three
macaques dual-infected with both R5 (SIVmac251) and X4 (SHIV-89.6P) viruses. CMPD 167 caused a rapid and substantial (on average, 50-
fold) suppression of R5 virus replication in each animal. In two of the animals, but not in the third, a rapid, transient, 8- to 15-fold increase in
the amount of plasma X4 virus occurred. In neither animal was the increase in X4 viral load sustained throughout therapy, however. These
observations may have relevance for the development of CCR5 inhibitors for treatment of HIV-1 infection of humans.
D 2004 Elsevier Inc. All rights reserved.
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CCR5 is a 7-transmembrane G-protein coupled receptor
for CC-chemokines that is also used as an entry coreceptor
by human immunodeficiency virus type 1 (HIV-1) (Berger
et al., 1999; Clapham and McKnight, 2002; Doms, 2001;
Schwarz and Wells, 2002). Most new HIV-1 infections
involve the transmission or early dominance of viruses that
use CCR5 (R5 strains), but HIV-1 can also use another
coreceptor, the CXC-chemokine receptor CXCR4 (Berger et0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.07.021
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Schwarz and Wells, 2002). CXCR4-using viruses (X4
strains) are only rarely transmitted, but if they emerge
during infection, the disease course is accelerated (Moore
et al., 2004; Richman and Bozzette, 1994; Schuitemaker
et al., 1992). One reason is that X4 viruses are inherently
more cytopathic than R5 strains (Grivel et al., 2000;
Etemad-Moghadam et al., 2001), another is that they target
naive CD4+ T-cells both in the periphery and in the thymus,
thereby also impairing T-cell production (Douek et al.,
2003; Hazenberg et al., 2000; McCune, 2001).
Entry inhibitors are an emerging class of drugs to treat
HIV-1 infection, and the first of them, Enfuvirtide (T-20) has
recently been licensed as a drug (Kilby and Eron, 2003;
Moore and Doms, 2003). One sub-class of entry inhibitors
comprises small molecules that bind to CCR5 and block its
coreceptor function, several of which are now in clinical
development (Kazmierski et al., 2003; Kilby and Eron,004) 19–29
Rapid Communication202003; Meanwell and Kadow, 2003; Moore and Doms, 2003;
Schwarz and Wells, 2002; Sobieszczyk et al., 2004; Strizki
et al., 2001). A long-standing concern with the clinical use
of CCR5 inhibitors is that they might indirectly promote the
replication of X4 strains and hence exacerbate disease
(Berger et al., 1999; Clapham and McKnight, 2002; Doms,
2001; Michael and Moore, 1999; Moore et al., 2004). This
could occur by the mutation of R5 viruses to favor CXCR4
use, although in vitro studies suggest that coreceptor
switching is not the usual escape pathway driven by the
small molecule inhibitors (Kuhmann et al., 2004; Trkola et
al., 2002) (JPM et al., unpublished results). Alternatively,
R5 viruses appear to suppress the replication of X4 viruses
under in vivo conditions (Harouse et al., 2003), so inhibition
of R5 virus entry might simply allow the expansion of pre-
existing X4 strains without the need for genetic inter-
conversion of an R5 virus to an X4 variant (Harouse et al.,
2003; Moore et al., 2004).
To address these issues, particularly the latter, we have
used a non-human primate model. Specifically, rhesus
macaques were dual-infected with both R5 (SIVmac251)
and X4 (SHIV-89.6P) viruses for 3 months until viral set
points were established, and then treated with a CCR5-
specific small molecule inhibitor, CMPD 167. We have
previously shown that CMPD 167 suppresses SIV repli-
cation in vitro and in vivo (Veazey et al., 2003), but like
other CCR5 inhibitors, it has no effect on SHIV-89.6P
replication (Veazey et al., 2003; Zhang et al., 2000). We
found in the present study that CMPD 167 caused a rapid
and substantial (on average, 50-fold) suppression of R5
virus replication in each test animal. In two of the dual-
infected animals, but not in the third, a rapid, transient, 8- to
15-fold increase in the amount of plasma X4 virus occurred.
In neither animal was the increase in X4 viral load sustained
throughout therapy.Results
Simultaneous quantification of R5 and X4 viral loads in
dual-infected animals
To be able to study the effect of a CCR5 inhibitor on both
R5 and X4 components of the total viral load in dual-
infected animals, it is necessary to quantify both viruses
simultaneously. We therefore developed a set of discrim-
inatory, real-time kinetic RT-PCR assays, using stringency-
matched primers based on the 5V-ends of the env genes of
SIVmac251 and SHIV-89.6P, and on a conserved region of
SIV gag. Thus, the env-based assays each detect only one of
the viruses, the gag-based assay detects both, because both
viruses contain the SIV gag gene.
A central feature of the assays is their use of an internal
control RNA transcript as a standard to allow accurate
determination of the copy number of each viral target. The
control transcript was created by end-to-end ligation of 500-nt fragments of SIVmac251 env, SHIV-89.6P env, and SIV
gag and insertion of the 1500-nt construct into vector
pCR2.1. We evaluated the specificity and sensitivity of the
final assay and established that we could routinely quantify
a low or negative copy number of one viral RNA even in the
presence of a substantial excess (N107-fold) of the other
(data not shown).
Dual-infection of a Chinese rhesus macaque
An initial experiment involving a Chinese rhesus
macaque infected simultaneously with both SIVmac251
and SHIV-89.6P demonstrated that both infecting viruses
could indeed be quantified simultaneously using a discrim-
inatory viral load assay. In this pilot study, we used an
earlier generation version of the assay that had separate, and
not interlinked, internal control transcripts, but we judge the
results to be broadly comparable to those derived using the
later-generation assay described above. In the test animal,
the levels of SIVmac251 and SHIV-89.6P viral load 60–90
days post-infection were found to be in the ranges 104–105
and 103–104 RNA copies/ml, respectively, an R5-X4 ratio
of approximately 10. Macaques of Chinese origin sustain
lower viral loads than those of Indian origin, and the rate of
disease progression is also reduced, so the viral loads we
measured are not unexpected (Ling et al., 2002). Of note
was that the sum of the measurements of the SIVmac251
and SHIV-89.6P env genes equaled the total value for SIV
gag, within the same log range (data not shown). Because
both infecting viruses contain the SIVmac251 gag gene, this
concordance attests to the appropriate performance of the
discriminatory viral load assay.
Dual-infection of Indian rhesus macaques, and effect of
CMPD 167 on viral load in a SIVmac251-infected animal
Two Indian rhesus macaques (AN15 and BEO8) were
simultaneously inoculated intravenously with SIVmac251
and SHIV-89.6P; two others (T369 and P137) were super-
challenged with SHIV-89.6P 8 months after intravaginal
SIVmac251 infection. Following dual infection, all four
macaques were monitored for 11 weeks so that a stable viral
bset pointQ was established. The final generation discrim-
inatory assay was used to monitor viral loads for the next
100–220 days.
One of the monkeys, P137, became infected with
SIVmac251 only, with no detection of SHIV-89.6P at any
time point. The viral load in this animal was quantified
using both the SIV env- and gag-based assays; there was
excellent concordance between the two measurements of
absolute and relative changes (Fig. 1). The baseline plasma
viremia level was in the range 2–4  105 RNA copies/ml
(Fig. 1). CMPD 167 was administered intravenously to
P137 using the same protocol that we had shown to cause
viral load reductions in other SIVmac251-infected animals
(Veazey et al., 2003). Thus, P137 received CMPD 167
Fig. 1. Effect of CMPD 167 on viral load in SIVmac 251-infected monkey P137. The RNA copy number/ml plasma is shown as a function of time (days). Time
0 marks the start of CMPD 167 therapy, which was given twice daily for 14 days, then once daily for a further 14 days. Viral load was measured using a
SIVmac251-gag ( ) or env ( ) assay.
Rapid Communication 21intravenously twice-daily for 14 days, then once-daily for a
further 14 days, the dosing reduction being IACUC-
mandated to reduce the cumulative exposure of test animals
to anesthesia.
A rapid and substantial reduction (2.0–2.3 log10) in viral
load occurred in P137 upon the initiation of CMPD 167
therapy, with a nadir being reached between days 6 and 8
(Fig. 1). There was a gradual rebound after dosing was
switched from twice- to once-daily on day 14. By the end of
the 28 days of therapy, viral load had returned approx-
imately to baseline, probably because of the sub-optimal
nature of therapy during the last 14 days; it remained near
the baseline value for the rest of the monitoring period (105
days). There was no significant change in CD4 count in
P137 during therapy; it remained fairly stable at approx-
imately 400 cells/Al (Fig. 2b). Overall, the plasma viremia
response to CMPD 167 in P137 was broadly consistent with
what we observed in six other SIV-infected macaques
(Veazey et al., 2003).
The other three animals, AN15, BE08, and T369, clearly
became infected with both challenge viruses (Figs. 2–4).
Total viral loads (gag-based assay) were in the range 105 to
107 RNA copies/ml by 50 days post-inoculation (Fig. 2a).
The ratio of the SIVmac251 and SHIV-89.6P viral loads
varied between 2.3 (T369) and 29 (AN15) at baseline (Fig.
3, Table 1). This is consistent with a previous report that the
R5 viral load was always the higher in macaques dual-
infected with R5 and X4 SHIVs (Harouse et al., 2003), and
with our observations in the dual-infected Chinese rhesus
macaque (see above).
The CD4 counts were very low in two of the three dual-
infected animals, but were preserved at an intermediate level
in T369 (Fig. 2b). SHIV-89.6P infection usually ablates
CD4 counts very rapidly, with peak SHIV-89.6P viremia
during primary infection predicting subsequent CD4 T cell
loss (Igarashi et al., 2003; Zhang et al., 2004). It is notablethat T369 had the lowest absolute SHIV-89.6P viral load of
the three dual-infected animals during primary infection
(Fig. 3b).
Effects of CMPD 167 on viral load in dual-infected animals
When CMPD 167 was administered intravenously to the
three dual-infected macaques, there was a rapid and
substantial decrease in SIVmac251 virus load in each of
the animals (Figs. 3 and 4). In AN15 and T369, the
maximum reductions were 25- and 40-fold, respectively,
reached by days 9–13, with the viral loads subsequently
rebounding after the switch to once-daily dosing, as had been
observed in the single-infected animal, P137 (Figs. 1,3). The
SIVmac251 viral load decline was slower but more sustained
in animal BE08, the nadir being a 50-fold reduction on day
23 (Fig. 3c). Despite daily observations and minimal clinical
signs, this monkey was found dead 3 weeks after the end of
therapy. Necropsy revealed cryptosporidiosis (consistent
with AIDS) as well as severe amyloidosis and chronic
endometriosis, the latter two diseases appear to have been
chronic in duration (both diseases are common in primates).
Viral load determinations for BE08 from the last few days of
therapy and post-therapy were not made using the final-
generation assay as too little blood was available, and so are
not plotted. However, the use of an earlier generation, less
precise assay had indicated that the trends shown in Fig. 3c
continued unchanged until the last sample, which was taken
on day 40 (data not shown).
Upon initiation of CMPD 167 therapy, the SHIV-89.6P
viral load increased substantially and rapidly in AN15 and
T369, reaching levels 11-fold and 7.5-fold higher than
baseline after 5 days (Figs. 3a,b). However, this elevation in
the X4 component of the total viral load was only transient.
In both animals, X4 viral load began to decline on day 8, and
in T369 it was below baseline from day 9 onward. In AN15,
Fig. 2. (a) Effect of CMPD 167 on total viral load in SIVmac 251- and SHIV-89.6P dual-infected monkeys AN15 ( ), T369 ( ) and BEO8 ( ), as determined
using a SIVmac251 gag-based PCR assay for the three dual-infected monkeys. (b) CD4+ cell counts per Al of peripheral blood for the 3 dual-infected animals
and the SIVmac251-infected animal P137(w). Day 0 indicates the first day of CMPD 167 treatment.
Rapid Communication22a smaller, second blip in X4 virus load occurred between
approximately days 15 and 25 (Fig. 3a). The doubling times
of the initial X4 viral load increases in AN15 and T369 were
1.1 and 1.3 days, respectively, comparable with the t1/2
values for the R5 viral load declines (Table 1). In the third
dual-infected animal, BE08, there was no increase in SHIV-
89.6P viral load during CMPD 167 therapy (Fig. 3c). After
therapy ceased, the X4 viral load was little or no higher than
the pre-therapy level in any of the three animals (Fig. 3). The
total viral load, measured using the gag-based assay,
fluctuated only a little during therapy in all three animals
because it represents the sum of the changing SIVmac251
and SHIV-89.6P viral loads (Fig. 2a). Thus, at early times,
the decrease in SIVmac251 viral load was countered by an
increase in SHIV-89.6P viremia, dampening the overall
decline in total viral load (Fig. 2a, Fig. 3).To better study the kinetics of changes, the R5 and X4
viral loads during therapy were expressed relative to the
baseline values (=1.0) (Fig. 4). The X4 viral load peak in
AN15 and T369 was reached slightly earlier than the trough
of the R5 decline, and the decline from the X4 peak occurred
while the R5 viral load was still suppressed, or even falling.
The R5/X4 viral load ratios varied markedly during therapy,
but a substantial decrease in the ratio occurred at the time of
the X4 viral load peak (Table 1). At this time, the R5 viral
loads were 9- and 40-fold lower than the X4 viral loads in
AN15 and T369, respectively. By the time CMPD 167
therapy ceased, however, the R5/X4 ratios were considerably
higher than pre-therapy values (Table 1), and fluctuated at
higher levels throughout the rest of the monitoring period.
No significant changes in CD4+ T-cell counts in the two
animals with very low baseline counts were observed during
Fig. 3. Effect of CMPD 167 on SIVmac251 R5 ( ) and SHIV-89.6P X4 ( ) viral load components in dual-infected monkeys AN15 (a), T369 (b), and BE08
(c). The viral load assays were based on env-specific primers and are shown in absolute terms (RNA copies/ml of plasma). Day 0 indicates the first day of
CMPD 167 treatment.
Rapid Communication 23CMPD 167 therapy (Fig. 2b). Animal T369 had maintained
an intermediate level of cells at the start of the CMPD 167
treatment period. During therapy, the CD4+ T-cell counts in
T369 trended downwards, but they diminished much moresharply once therapy ceased (Fig. 2b). A similar pattern of
changes in CD4+ T-cell count was observed in the
SIVmac251 single-infected animal P136 during and after
CMPD 167 treatment. Thus, although T369 was one of the
Fig. 4. Effect of CMPD 167 on SIVmac251 R5 ( ) and SHIV-89.6P X4 ( ) viral load components in dual-infected monkeys AN15 (a), T369 (b) and BE08 (c).
The viral load values are normalized to those at the start of CMPD 167 therapy (day 0), and are derived from those presented as absolute values in Fig. 3.
Rapid Communication24two dual-infected monkeys in which transient X4 viral load
increases occurred, it is not obvious that this was linked to
any change in CD4+ T-cell count. Indeed, the drop in CD4+T-cell count post-therapy in animals T369 and P137
suggests that administration of CMPD 167 might have
helped to reduce the rate of T-cell loss during therapy. There
Table 1
Kinetics of viral load changes, and relative viral loads, were monitored in SIVmac251 (R5)-infected and dual (R5 and X4)-infected macaques during and after
CMPD 167 therapy
Macaque 251 env tO
(days), [R2]
89.6P env t2
(days), [R2]
Baseline
log10
R5 VL
at start of
treatment
Baseline
log10 X4 VL
at start of
treatment
log10
reduction
in R5 VL
from start
of treatment
to nadir
R5/X4
day 1
R5/X4 at
X4 peak
(day)
R5/X4 at
R5 nadir
(day)
R5/X4
at tmt
end (day)
R5/X4
follow-up
(day)
P137 1.1 [0.88] NA 5.6 NA 2.0 NA NA NA NA NA
AN15 1.6 [0.97] 1.1 [0.99] 5.2 3.8 1.4 29 0.11 (7) 0.57 (13) 69 (34) 49 (148)
T369 1.4 [0.92] 1.3 [0.95] 5.5 5.1 1.6 2.3 0.024 (5) 0.10 (9) 420 (34) 8.0 (132)
BE08 1.1 [0.97] NA 6.9 6.4 1.7 2.8 NA 0.033 (23) ND ND
[R2] is the squared correlation coefficient for the logarithmic VL (viral load) as linear a function of time. The baseline represents VL at the start of therapy. NA=
not applicable. ND = not done.
Rapid Communication 25was no change in total blood monocyte count in any of the
animals during therapy (data not shown).Discussion
An obvious limitation of this study is the limited number
of dual-infected animals we have been able to study to date,
which restricts the certainty of any conclusions that can be
drawn. Within that constraint, our principal observation is
that the suppression of R5 virus production by a CCR5
inhibitor in vivo was associated with an increase in X4 virus
load in 2 of 3 dual-infected animals. However, this increase
was only transient, and after 10 days of therapy, the X4
virus load was little or no greater than before therapy was
initiated. In the third dual-infected animal, the CCR5
inhibitor had no effect on X4 virus load. In all three
animals, plus the animal infected with SIVmac251 only, the
R5 viral load was reduced significantly by the CCR5
inhibitor, at least during the period of optimal, twice-daily
dosing. The t1/2 values for the SIVmac251 viral load decline
in the dual-infected animals (1.1–1.6 days; Table 1) were
similar to values for singly infected animals in this (1.1
days, Table 1) and our previous study (average 0.94 F 0.18
days) (Veazey et al., 2003). The mean maximum R5 viral
load decrease in the dual-infected animals was 1.6 F 0.15
log10, identical to the decrease in the seven singly infected
animals in this and the previous study (1.6 F 0.5 log10).
Thus the presence of an X4 virus does not impair the
activity of a CCR5 inhibitor against an R5 virus in vivo. The
SIVmac251 viral load reductions in the single- and dual-
infected animals (1.6 log10) are also comparable to the
average viral load reductions seen during 10-day dosing
trials of humans with other small molecule CCR5 inhibitors
(1.50 log10 for SCH-C at 100mg, BID; 1.62 log10 for SCH-
D at 50 mg BID; 1.42 log10 for UK-427,857 at 100 mg,
BID) (M. Laughlin, Schering Plough and C. Hitchcock,
Pfizer, UK, personal communications). This concordance is
noteworthy given the differences in the inhibitors, infecting
viruses (SIV vs. HIV-1) and species between the various
studies.The overall patterns of R5 viral load responses to CMPD
167 in the dual-infected animals were consistent with ones
we observed in SIV single-infected animals in this study
(P137; Fig. 1) and in our previous one (Veazey et al., 2003).
The SIVmac251 viral load rebounds in animals AN15 and
T369 during the later stages of CMPD 167 therapy again
probably reflect the sub-optimal nature therapy during this
period. Another possible explanation is the development of
outright resistance to CMPD 167. The latter could be due to
the acquisition either of the ability to use CCR5 despite the
presence of the inhibitor, or of an increased capacity to use
alternative, unidentified coreceptors, although probably not
CXCR4 (Veazey et al., 2003; Zhang et al., 2000).
How a reduction in R5 virus replication can lead to a
transient increase in X4 viral load remains to be determined.
The increase was very rapid, as quick as the decline in R5
viral load that is directly caused by the CCR5 inhibitor.
Under the conditions of our study, it cannot represent
mutation of the R5 SIVmac251 virus into an X4 variant, as
the assay used to quantify the X4 viral load is specific for
SHIV-89.6P. Nor is such a mutation likely to occur rapidly,
given the general inability of SIV strains to use CXCR4 as a
co-receptor (Berger et al., 1999; Clapham and McKnight,
2002; Doms, 2001; Moore et al., 2004; Schwarz and Wells,
2002). Moreover, we have shown previously that CMPD
167 does not affect SHIV-89.6P replication in the absence of
an R5 virus, in vitro or in vivo (Veazey et al., 2003). It has
been argued that R5 viruses might actively suppress the
replication of X4 viruses, in both dual-infected humans and
macaques (Harouse et al., 2003; Lee et al., 2000; Moore et
al., 2004). Our results are consistent with this hypothesis.
Thus, we show that an X4 viral load increase can occur
when both R5 and X4 viruses are present, and the R5
component is suppressed; pre-existing X4 viruses may
therefore fill a niche vacated by the R5 strains, at least
temporarily (Harouse et al., 2003; Moore et al., 2004).
One possible mechanism for an interaction between R5
and X4 strains in vivo is that competition might occur
between CXCR4 and CCR5 for a limiting amount of CD4
on the surface of some cells (Lee et al., 2000). Such a
mechanism would be most likely to operate when the cell
Rapid Communication26surface CD4 density is low, as it is, for example, on
macrophages (Lee et al., 2000; Lewin et al., 1996; Tokunaga
et al., 2001). Thus, it has been shown that a CCR5-blocking
chemokine, RANTES, can increase Env-mediated fusion
via CXCR4 on human macrophages (Lee et al., 2000). By
extrapolation, perhaps blocking CCR5 with CMPD 167
renders more CD4-CXCR4 complexes available for an X4
virus to use. It may be relevant that, when an X4 SHIV has
depleted most of the CD4+ T-cells from a macaque, most of
the X4 viral load is derived from macrophages (Igarashi et
al., 2001, 2002). In passing, we note that this must
presumably apply also to the production of SIVmac251
under the same circumstances because the dual-infected
animals sustained very high levels of SIVmac251 replica-
tion despite, in two cases, having extremely low peripheral
CD4+ T-cell counts (Fig. 2b).
It seems unlikely that changes in acquired immune
responses could occur quickly enough to account for the
rapid increase in X4 virus replication upon CMPD 167
administration. Alteration in innate immunity profiles,
particularly levels of chemokines or pro-inflammatory
cytokines, could, perhaps, occur quickly enough to be
relevant. For example, if a CCR5 inhibitor somehow caused
a decrease in SDF-1 expression that could in turn increase
X4 virus production (Berger et al., 1999; Clapham and
McKnight, 2002; Doms, 2001; Moore et al., 2004; Schwarz
and Wells, 2002). Another possibility is that the RANTES-
antagonist property of CMPD 167 might increase extrac-
ellular RANTES concentrations sufficiently for the latter to
enhance the replication of X4 viruses, a phenomenon that
can occur in vitro (Dolei et al., 1998; Gordon et al., 1999;
Kinter et al., 1998; Trkola et al., 1999). In vitro studies of the
effects of chemokines on virus replication do have predictive
limitations, however. Under in vitro conditions, for example,
in lymphoid tissue blocks, the replication of X4 viruses is
clearly dominant over that of R5 strains during dual-
infection experiments (Grivel and Margolis, 1999; Grivel
et al., 2000; Ito et al., 2004; Malkevitch et al., 2001), whereas
the converse situation appears to apply in vivo (Harouse et
al., 2003; Michael and Moore, 2001; Moore et al., 2004).
Although X4 viral load did increase after addition of
CMPD 167 in two of the test animals, it then almost as
rapidly declined. Again, the reasons are obscure, but one
explanation might be that the highly cytopathic SHIV-89.6P
virus quickly kills a pool of target cells that it was newly
able to infect, perhaps a subset of tissue macrophages
(Igarashi et al., 2001, 2002; Lee et al., 2000). There were,
however, no detectable changes in the counts of CD4+ T-
cells or monocytes in the peripheral blood of the test
animals during the period of CMPD 167 infusion (Fig. 2b,
and data not shown). It is possible that target cell destruction
occurred within other body compartments that we were not
able to sample during this study.
We noted earlier that we have been able to study a small
number of monkeys to date, and ones that are infected with
a very aggressive X4 virus. Clearly, additional animals willneed to be studied before we can draw definitive con-
clusions, and we will need to build into future experiments
what we have learned from the present, exploratory one.
Another limitation is that we are not addressing here the
possible long-term evolution of an R5 virus into an X4
strain, either as an escape mechanism under the selection
pressure of a CCR5 inhibitor, or spontaneously. Our focus in
this study has been on the immediate responses of the R5
and X4 components of a mixed infection to perturbation by
a CCR5 inhibitor. Based on in vitro studies, the most
common mechanism of evolutionary escape from CCR5
inhibitors may also not involve switching to CXCR4 use
(Kuhmann et al., 2004; Trkola et al., 2002) (JPM et al.,
unpublished results). However, other escape pathways could
incur risks associated with a broadening of viral tropism in
vivo (Gorry et al., 2002; Kuhmann et al., 2004).
Despite the caveats noted earlier, our results may still be
relevant to the development of CCR5 inhibitors for human
use (Kazmierski et al., 2003; Kilby and Eron, 2003;
Meanwell and Kadow, 2003; Moore and Doms, 2003;
Schwarz and Wells, 2002; Sobieszczyk et al., 2004; Strizki
et al., 2001). It is too early to know how such drugs would
be used if they are licensed. One obvious strategy is to
administer them only to individuals who have been screened
to exclude the overt presence of X4 viruses (Moore and
Doms, 2003). But it is clearly possible that CCR5 inhibitors
might sometimes be given to individuals that harbor X4
viruses, perhaps at levels below the limit of detection of
viral phenotype assays (Shankarappa et al., 1999). There
have, in fact, already been two examples of the admin-
istration of CCR5 inhibitors to humans who harbored
detectable levels of X4 viruses (diagnosed retrospectively)
during Phase I clinical trials. In one case, the X4 viral load
increased as the R5 viral load declined over the scheduled
10-day dosing period with the CCR5 inhibitor. When
therapy ceased, the X4 viral load rapidly reverted to
baseline (C. Hitchcock, Pfizer, UK, personal communica-
tion). In the second case, the total viral load was reduced by
approximately 0.5 log10 during therapy then returned to
baseline after therapy ceased; no information is yet available
on whether specific changes in the X4 component occurred
(M. Laughlin, Schering Plough, personal communication).
It is clearly not possible to draw definitive conclusions from
anecdotal observations in two humans, or from the limited
numbers of macaques that we have been able to study to
date. However, the transience of the X4 viral load increases
in animals AN15 and T369 does suggest that any increased
X4 virus production occurring when dual-infected humans
are dosed with CCR5 inhibitors might not always be
sustained, even if the therapy is maintained. Larger scale
human clinical trials will presumably provide an answer to
this question, one which is central to the practical develop-
ment of CCR5 inhibitor therapy.
In any eventuality, CCR5 inhibitors will surely be
combined with other, more traditional drugs to further
suppress HIV-1 replication and minimize escape. Early
Rapid Communication 27reports from small scale studies suggest that conventional
HAART is more effective against X4 than R5 viruses, which
would tend to minimize the evolution of X4 strains under
these conditions (Equils et al., 2000; Galan et al., 2004;
Philpott et al., 2001). Clearly, these complex issues will only
be finally resolved by the conduct of carefully designed and
thoroughly monitored human trials as the CCR5 inhibitors
progress through clinical development.Macaque studies such
as the one described here might help with the design and
interpretation of such trials, as well as throwing light on the
underlying virology and cell biology of primate immunode-
ficiency virus infection, particularly the usage of the CCR5
and CXCR4 coreceptors under in vivo conditions.Methods
Real-time PCR assays for R5 and X4 viral loads
Three independent Taqman assays were developed to
detect and quantify RNA molecules derived from the
SIVmac251 gag, SIVmac251 env, or SHIV-89.6P env genes.
Specifically, the following primers and probes were chosen
based on the recommendations of the Primer Express
(Applied Biosystems) application. For the SIVmac251 gag
assay, the forward primer was SIV gag 61F, cca cct (ag)cc att
aag ccc ga; the reverse primer was SIV gag 143R, ctg gca cta
ctt ctg ctc caa a and the probe was SIV gag 84T FAM_QSY,
cat taa atg cct ggg taa aat tga tag agg a(ga)a aga a. For the
SIVmac251 env assay, the forward primer was SIV251
env7F, tgt ctt ggg aat cag ctg ctt, the reverse primer was
SIV251 env94R, cac cat aaa aga ctg tga cat att gag tac, and
the probe was SIV-251 env30T FAM_QSY, cgc cat ctt gct ttt
aag tgt cta tgg gat cta t. For the SHIV-89.6P env assay, the
forward primer was SHIV 89.6 env 53F, gca cca tgc tcc ttg
gga t, the reverse primer was SHIV 89.6 env, 147R ggt tgc ttc
tct cca cac agg t, and the probe was SHIV 89.6 env 85T
FAM_QSY, agt gct aca gaa aaa ttg tgg gtc aca gtc tat tat gg.
Each probe was synthesized with FAM as the reporter
dye and a dark dye quencher. Individual Taqman reactions
were performed using the bOne step RT-PCR master mixQ
from Applied Biosystems according to the manufacturer’s
recommended conditions, and with 3.3 pmol of each primer
and 1.6 pmol of each probe. Cycling was performed on an
Applied Biosystems 7900 Sequence Detector as follows: 50
8C for 30 min, then 95 8C for 10 min, followed by 45 cycles
of 95 8C for 15 sec, and 60 8C for 1 min. Fluorescence data
were collected at each step of the PCR cycle and were
analyzed using the Applied Biosystems SDS2.1 software
system. The linear range of amplification for all three assays
was between 50 copies and 5  107 RNA copies per ml of
plasma. All assay results were reproducible, with little
assay-to-assay discrepancy.
To make the internal control transcript for each target,
approximately 500 base pairs surrounding the Taqman assay
site were amplified by PCR from a pure viral stock.Restriction sites were incorporated into the PCR primers to
allow the three fragments to be ligated together. This
construct of SIVmac2521 gag, SIVmac251 env, and SHIV-
89.6P env was ligated into vector PCR2.1 (Invitrogen). After
sequencing to determine the exact sequence and length of the
insert, the vector was linearized and used as a template for
RNA transcription from the T7 promoter. The resulting RNA
transcripts were purified from the DNA vector, then
quantified using a spectrophotometer quantified to measure
the OD 260/280 ratio. Known amounts were used to generate
the standard curves for quantification of each target, with the
standards containing between 10 and 1  108 input copies.
Infection of rhesus macaques and administration of CMPD
167
Macaques T369 and P137 were intravaginally inoculated
with 640 TCID50 of SIVmac251 and 8 months later, super-
infected by intravenous inoculation with 20 TCID50 of
SHIV-89.6P. Macaques AN15 and BE08 were simultane-
ously intravenously infected with 100 TCID50 of SIV-
mac251 and 20 TCID50 of SHIV-89.6P on the same day the
other animals were inoculated with SHIV-89.6P. Viral loads
were monitored for 11 weeks after the dual challenge of all 4
macaques, until stable set points had been reached. The
animals then received CMPD 167 (10 mg/kg) intravenously
by bolus injection, twice-daily for 14 days, then once-daily
for a further 14 days, the change being IACUC-mandated to
minimize cumulative exposure to anesthesia (Veazey et al.,
2003). Plasma viral loads were monitored 1–2 times daily
during treatment, then at least weekly for 6 weeks after
therapy ceased. CD4 counts were determined as described
previously (Veazey et al., 2003).Acknowledgments
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